智通财经APP获悉，9月29日，诺和诺德(NVO.US)宣布已向FDA递交依柯胰岛素(icodec)和Mim8的上市 申请，前者用于治疗2型糖尿病，后者用于治疗A型血友病。目前，依柯胰岛素已在欧盟和中国获批用 于治疗2型糖尿病。 依柯胰岛素是诺和诺德在口服胰岛素OI338的基础上设计的一款超长效胰岛素制剂，人体内半衰期长达 196h。其核心设计在于：①将18C长链脂肪酸替换为20C长链脂肪酸，提高分子与人血清白蛋白的结合 亲和力;②将B链16位Tyr(酪氨酸)替换为His(组氨酸)，降低分子对人胰岛素受体的亲和力。 诺和诺德曾在2023年4月第一次向FDA提交依柯胰岛素的生物制品许可申请(BLA)，当时申请的适应症 为1型糖尿病和2型糖尿病。2024年5月，FDA内分泌和代谢药物咨询委员会召开会议讨论了依柯胰岛素 治疗1型糖尿病的获益与风险。最终，委员会认为现有数据不足以得出依柯胰岛素治疗1型糖尿病的获 益-风险情况呈积极的结论。此次重新递交BLA，诺和诺德将依柯胰岛素的适应症缩小至2型糖尿病，申 请依据包括5项III期ONWARDS研究。 血友病是一种罕见的遗传性出血性疾病，会损害人体形成血栓的能力，而血栓 ...

I have been closely following Novo Nordisk ( NVO ) ( OTCPK:NONOF ) ( NVON:CA ) for almost a year now, and I can't forget when it was considered the best European company. In such a short amountHi there, welcome to my profile. My name is Eugenio Catone, I live in Italy and I am 27 years old.In 2023 I graduated in Business Administration and I completed CFA level 1 in 2024. I am currently a Popular Investor on the investing platform eToro, you can see there my public portfolio. My interest in financial market ...

Virtual care provider LifeMD (NASDAQ:LFMD) announced on Tuesday that it has expanded its existing partnership with Novo Nordisk (NVO) to offer the Danish drugmaker’s diabetes therapy Ozempic through its telehealth platform. The company added that thanks to its integration with ...

Morgan Stanley downgraded and cut the price target on Novo Nordisk shares, citing GLP-1 concerns. https://t.co/nKBbrTqThp ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Market Overview - The U.S. stock market is expected to open cautiously, with major index futures indicating a slight pullback due to concerns over a potential government shutdown and upcoming economic data releases [1][2] - September has been a positive month for major indexes, with the Nasdaq Composite gaining approximately 5.3%, the S&P 500 advancing around 3.1%, and the Dow Jones Industrial Average rising about 1.7% [3] Premarket Trading and Futures Movements - S&P 500 futures were down approximately 0.18% to 0.2%, Dow Jones Industrial Average futures declined around 0.18% to 0.23%, and Nasdaq 100 futures edged lower by about 0.16% to 0.21% [2] Corporate Earnings and Stock Movements - Nvidia (NVDA) shares rallied over 2% on Monday, settling above the $180 level, and rose 1% in premarket trading [6] - Electronic Arts (EA) surged after reports of a $55 billion going-private leveraged buyout deal, with the stock jumping 15% on Friday and climbing a further 4.5% on Monday [6] - Intel (INTC) shares were down almost 3% on Monday after a significant 20% surge last week [10] - Robinhood Markets (HOOD) saw its shares surge over 12% on Monday, closing at an all-time high [10] - Western Digital (WDC) rose 9.2% and Seagate Technology (STX) added 5.3% after analysts raised price targets due to growing demand for hard drives to support AI [10] - Coinbase Global (COIN) gained 6.8% as major cryptocurrencies moved higher [10] - Lam Research (LRCX) shares rose 3.3% after Deutsche Bank upgraded the company to a "Buy" rating [10] - Novo Nordisk (NVO) dropped 3% after receiving a downgrade to "Underweight" [10] - The energy sector was the worst-performing sector in the S&P 500 on Monday, declining 1.9% [10] Upcoming Economic Data - Key reports to be released include the Job Openings and Labor Turnover Survey (JOLTS) for August, Consumer Confidence Report for September, and Chicago Region's Business Activity Data for September [6] - The JOLTS report is expected to provide insights into labor market health, while the Consumer Confidence Report will reflect household sentiment amidst inflation concerns [6]

Group 1: Granolas Sector Analysis - The Granolas sector, which includes major European companies, has underperformed the European market index by approximately 25% since early 2024, with its market capitalization dropping from 27% to 20% of the overall European market [2] - Despite weak stock performance, Granolas' earnings have not deteriorated, with an expected earnings growth rate of 8% for 2025, while overall European market earnings are projected to remain flat [2] - The valuation issues of Granolas have been corrected, with the current price-to-earnings ratio at a 6% discount compared to the median of the past 10 years, indicating a return to reasonable levels [2] - Granolas' free cash flow yield has improved, and cash reserves on the balance sheet increased from €91 billion in 2023 to €106 billion in 2024, with stock buybacks projected to rise from €23 billion in 2023 to an annualized €36 billion in 2025 [2] Group 2: French Stock Market Outlook - The French stock market has underperformed the market by about 15% over the past two years, with bank stocks lagging behind Eurozone peers by as much as 30% [4] - Currently, the French stock market is trading at a significant discount compared to the STOXX 50 index, a situation historically seen only during major crises [4] - Morgan Stanley believes that the long-term bond yields in France are unlikely to continue rising, and the negative impact from the government's failure to pass a confidence vote may temporarily dissipate, presenting attractive investment opportunities [4] - Despite high uncertainty, including potential future confidence votes, there is a possibility of reaching a budget plan acceptable to the market, and any negative impact from re-elections on risk assets may be short-lived [4]

Denmark’s gross domestic product grew less than previously reported in the second quarter as the slowdown of drugmaker Novo is fueling concern about the national economy https://t.co/pQ2WriRx4l ...

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]

Key Points An analyst downgraded his recommendation on the Danish pharmaceutical's equity. He changed it from the equivalent of hold to buy. 10 stocks we like better than Novo Nordisk › Drug tariffs, tough competition, and a fresh analyst recommendation downgrade were the burdens pulling down Novo Nordisk (NYSE: NVO) stock on Monday. In some respects, then, it was surprising that the company's shares didn't do worse than the 0.2% slump they were hit with across that trading session. Meanwhile, the ...